suPARnostic® Approval in India

Wed Jun 06 2018

The suPARnostic® product has been approved by the Central Drugs Standard Control Organisation, New Delhi, and given permission to import, for which Form 10 license was issued in May 2017.

Congratulations to our distributor Super Biotech Pvt Ltd, who already has trials of the suPARnostic® product running at several hospitals in India.

Super Biotech Pvt Ltd has added a new phone number +91 11 45073677 specially for suPAR inquiries in India.

Contact information to Super Biotech – please see here

900+

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

View product

TurbiLatex

For Automated Systems

View product

ELISA Assay

Clinical and Research

View product

POC+

Point-of-care finger prick

View product

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

View recording

New Webinar – View recording

suPARnostic® by ViroGates